| Literature DB >> 34894940 |
Mohamed Mokhtar Mohamed Abdelahi1, Youness El Bakri1,2, Chin-Hung Lai3,4, Karthikeyan Subramani5, El Hassane Anouar6, Sajjad Ahmad7, Mohammed Benchidmi1, Joel T Mague8, Jelena Popović-Djordjević9, Souraya Goumri-Said10.
Abstract
An efficient pathway was disclosed for the synthesis of 3-chloro-6-nitro-1H-indazole derivatives by 1,3-dipolar cycloaddition on dipolarophile compounds 2 and 3. Faced the problem of separation of two regioisomers, a click chemistry method has allowed us to obtain regioisomers of triazole-1,4 with good yields from 82 to 90% were employed. Also, the antileishmanial biological potency of the compounds was achieved using an MTT assay that reported compound 13 as a promising growth inhibitor of Leishmania major. Molecular docking demonstrated highly stable binding with the Leishmania trypanothione reductase enzyme and produced a network of hydrophobic and hydrophilic interactions. Molecular dynamics simulations were performed for TryR-13 complex to understand its structural and intermolecular affinity stability in a biological environment. The studied complex remained in good equilibrium with a structure deviation of ∼1-3 Å. MM/GBSA binding free energies illustrated the high stability of TryR-13 complex. The studied compounds are promising leads for structural optimisation to enhance the antileishmanial activity.Entities:
Keywords: 1,2,3-Triazole; antileishmanial activity; isooxazoline; isoxazole; molecular dynamics
Mesh:
Substances:
Year: 2022 PMID: 34894940 PMCID: PMC8667887 DOI: 10.1080/14756366.2021.1995380
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Scheme 1.Synthesis of dipolarophiles 2 and 3.
Scheme 2.Synthesis of new isoxazoline-6-nitro-1H-indazole derivatives.
Scheme 3.Synthesis of new 1,2,3-triazolyl methyl-6-nitro-1H-indazole derivatives.
Scheme 4.Synthesis of new 1,2,3-triazolylmethyl-6-nitro-1H-indazole derivatives under catalytic condition.
Scheme 5.Synthesis of new isoxazole-6-nitro-1H-indazole derivatives.
Figure 1.The molecules tested against leishmanias.
Inhibitory concentration (IC50) values in μM of twelve synthetic compounds (4–15) against promastigotes.
| Molecules |
|
|
|
|---|---|---|---|
| 4 | >500 | >500 | 15.53 |
| 5 | >500 | >500 | 11.23 |
| 6 | >500 | >500 | >500 |
| 7 | >500 | >500 | 328.59 |
| 8 | >500 | >500 | 280.84 |
| 9 | >500 | >500 | >500 |
| 10 | >500 | >500 | 174.12 |
| 11 | >500 | 213.44 | 16.85 |
| 12 | >500 | >500 | 102.03 |
| 13 | 106.72 | >500 | 308.93 |
| 14 | >500 | >500 | >500 |
| 15 | >500 | >500 | >500 |
| Control Glucantime® | >500 | >500 | >500 |
Lower IC50 indicates concentration of the compounds required to kill the organism by 50%.
Figure 5.The role of the substituent functional groups on SAR of the synthesised compounds.
Figure 6.The role of the basic skeleton on SAR of the synthesised compounds.
Docking binding energies, number of hydrogen bonds and number of closest residues to the docked ligands (4, 5, 11, and 13) within the active binding site of the targeted TryR.
| Name of synthesised derivatives | Free binding energy (kcal/mol) | H-bonds (HBs) | Number of closest residues to the docked ligand into the active site | IC50 (µM) |
|---|---|---|---|---|
|
| −9.33 | 0 | 8 | 15.33 |
|
| −10.10 | 0 | 9 | 11.23 |
|
| −9.26 | 1 | 8 | 16.85 |
|
| −9.00 | 5 | 9 | 308.93 |
Figure 9.The (a) RMSD (b) RMSF analysis plot of TryR-13 complex system.
Figure 10.(a) SSE distribution by residue index throughout the TryR structure (b) SSE composition for each trajectory frame over the course of the simulation TryR secondary structure elements (SSE) like alpha helices and beta strands are monitored throughout the simulation.
Figure 11.(a) TryR-13 contacts during 50 ns simulation (b) a schematic representation of the interaction between 13 and the TryR residues.
Figure 12.Different MM/GBSA binding free energies of compound 13-TryR complex.